genicity are other disadvantages associated with the use of live bacteria as immunotherapeutic agents (Lagranderie et al, 1996; Zlotta et al, 1997a Zlotta et al, , 1997b , and this has led to the development of other less toxic but effective biological response modifiers. A nonviable mycobacterial cell wall extract (MCWE, US Patent No. 4 744 984) derived from Mycobacterium phlei (M. phlei) has been shown to have anti-cancer activity. Intravesical therapy with MCWE formulated as a mineral oil emulsion (Regression®, Bioniche, London, Ontario, Canada) has been shown to reduce cancer burden in orthotopic and heterotopic murine bladder cancers (Kadhim et al, 1993; Chin et al, 1996) and in patients with carcinoma in situ of the bladder (Morales and Chin, 1997) .
MCWE is derived from M. phlei, a Gram-positive microorganism that is not a recognized pathogen for fish, amphibia, birds and mammals. This ubiquitous mycobacteria can be found in soil, on plants and in drinking water (Mallick et al, 1985; Papapetropoulou et al, 1997) . MCWE is a partially delipidated and deproteinized macromolecular complex composed primarily of carbohydrates, peptides and lipids. These molecules form the basis of the two major components of the cell wall, peptidoglycan and glycolipid (Chin et al, 1996) . Although the mechanism of action of MCWE against bladder cancer is unknown, M. phlei has been reported to be a potent immunostimulator active against viral and parasitic infections (Mallick et al, 1985; Tewari et al, 1996) .
M. phlei mycobacterial cell complex (MCC) is a cell wall composition wherein the mycobacterial DNA is preserved and complexed on the cell wall surface. We have found that MCC preparations contain approximately 5-10% of M. phlei-derived DNA, primarily in the form of short oligonucleotides . We have found that MCC has the ability to induce in vitro and in vivo the synthesis of a number of human and mouse cytokines (Filion et al, 1998) . Because of the reported anti-cancer activity of interleukin 12 (IL-12) towards some cancer cell lines (Izquierdo et al, 1996; Stine et al, 1996) and the stimulatory activity of granulocyte-macrophage colony-stimulating factor (GM-CSF) on bladder cancer cell proliferation (Hawkyard et al, 1993) , we felt it appropriate to determine whether MCC could induce the synthesis of these anti-and procancer cytokines by bladder cancer cells. We have also determined whether MCC could induce IL-6, which has been shown to function either as a growth factor (Okamato et al, 1997) or as an antiproliferative factor for bladder cancer lines (Alexandroff et al, 1997) .
In this report we have (a) evaluated the ability of MCC to induce the synthesis of IL-6, IL-12 and GM-CSF by human HT-1197 and HT-1376 bladder cancer cells, and (b) capacity to induce the synthesis of IL-12, IL-6 or GM-CSF by bladder cancer cells. However, MCC is a potent inducer of IL-12 and IL-6, and a poor inducer of GM-CSF synthesis by monocytes and macrophages. Furthermore, we show that MCC is able to directly inhibit the proliferation of HT-1197 and HT-1376 transitional cell carcinoma. MCC does not appear to be directly toxic towards these cancer cells: it does, however, induce apotosis. We found that M. phlei DNA associated with MCC is responsible for the induction of apoptosis. Our results indicate that MCC may possess a direct action against human bladder cancer cells after intravesical administration by inducing apoptosis, and an indirect action by stimulating cancer-infiltrating monocytes/macrophages to synthesize IL-12.
MATERIALS AND METHODS

Cells
HT-1197 and HT-1376 are cancer cell lines developed from anaplastic transitional cell carcinomas of the bladder taken from a 44-year-old Caucasian man (grade 4) and a 58-year-old Caucasian woman (grade 3) respectively (Rasheed et al, 1977) . HT-1197 and HT-1376 cells were obtained from the American Type Tissue Culture Collection (ATCC; Rockville, MD, USA) and were grown in modified Eagle medium (MEM) supplemented with non-essential amino acids and vitamins and containing 10% fetal calf serum (FCS) (MEM-FCS; all from Gibco Life Science, Burlington, Ontario, Canada). Human monocytic THP-1 cells and murine monocytic RAW 264.7 cells obtained from the ATCC were cultured in RPMI-1640 medium supplemented with 10% FCS, 2 mM L-glutamine and 20 mM Hepes (all from Gibco Life Science). Murine macrophages were obtained from female CD1 mice injected i.p. with 1.5 ml sterile Brewer's thioglycolate broth (Difco, Detroit, MI, USA). The peritoneal exudate (> 85% macrophages) was harvested at day 4, washed by centrifugation in Hanks' balanced salt solution (HBSS) and seeded in 6-well flat bottom microplates at 1.0 × 10 6 cells ml -1 in the medium described for monocytes. The cells were allowed to adhere for 18 h at 37°C in an atmosphere of 5% carbon dioxide, after which non-adherent cells were removed by gentle washing with warm medium. Murine spleen cells were prepared by gentle teasing through sterile stainless-steel screens. Cell suspensions were layered on Lympholyte-M cell separation media (CedarLane, Hornby, Ontario, Canada) and centrifuged at 2200 r.p.m. for 30 min to remove red blood cells and dead cells. The cells were cultured in the culture medium described above. All cells were cultured at 37°C in an atmosphere of 5% carbon dioxide.
Cytokine analysis
Cells were seeded at 1 × 10 6 cells ml -1 in 6-well flat-bottomed tissue culture plates and treated with different concentrations of MCC for 48 h. Human (h) and murine (m) IL-6, IL-12 and GM-CSF synthesis was measured after 48 h by means of commercial enzyme-linked immunosorbent assay (ELISA) (all from BioSource, Camarillo, CA, USA, except murine GM-CSF which was from R&D Systems, Minneapolis, MN, USA). The ELISA sensitivities were: 8 pg ml -1 for mIL-6, 2 pg ml -1 for mIL-12, 1 pg ml -1 for mGM-CSF, 104 fg ml -1 for hIL-6, 1 pg ml -1 for hIL-12 and 1 pg ml -1 for hGM-CSF.
Proliferation assay
HT-1197 and HT-1376 cells were incubated in 1.0 ml MEM-FCS at 3 × 10 5 cells in six-well flat-bottomed tissue culture plates with MCC, Escherichia coli 011:B4 lipopolysaccharide (LPS; SigmaAldrich Canada, Oakville, Ontario, Canada) or recombinant hIL-12 (R&D Systems) for 20 h at 37°C in an atmosphere of 5% carbon dioxide. Cellular growth was measured by determination of dimethylthiazoldiphenyltetrazolium bromide (MTT) reduction (Mosman et al, 1983) . Briefly, 100 µl of MTT (Sigma-Aldrich) dissolved in PBS at 5 mg ml -1 was added to wells and incubated at 37°C for 4 h. Acid-isopropanol (1.0 ml of 0.04 N hydrochloric acid in isopropanol) was then added, and reduced MTT was measured at a wavelength of 570 nm.
MCC toxicity determination
HT-1197 or HT-1376 cells were incubated in 1.0 ml of MEM-FCS at 3 × 10 5 cells in 6-well flat-bottomed tissue culture plates with MCC for 48 h. Lactate dehydrogenase (LDH) activity in the supernatant was used as an indicator of cell death, and was determined by means of a commercial kit (Sigma-Aldrich). Total LDH activity was determined by incubating macrophages in 1.0% v/v Triton X-100 in water to induce lysis, followed by vigorous agitation .
Analysis of apoptosis
HT-1197 or HT-1376 cells were incubated in 1.0 ml MEM-FCS at 3 × 10 5 cells in six-well flat-bottomed tissue culture plates with 1 µg ml -1 of MCC or with 1 ng ml -1 of IL-12 for up to 48 h. After incubation, non-adherent cells in the supernatant were collected by centrifugation at 200 g for 10 min. The pellet or remaining adherent cells were lysed with 0.5 ml of hypotonic lysing buffer, pH 7.5 (10 mM Tris buffer, 1 mM EDTA, 0.2% Triton X-100). The lysates were centrifuged at 13 000 g for 10 min and the supernatants containing fragmented DNA were precipitated overnight at -20°C in 50% isopropanol and 0.5 M sodium chloride. The precipitates were collected by centrifugation and analysed by electrophoresis in 0.7% agarose gels for 3 h at 100 V (Newell, 1990) . Apoptosis was also determined by an ELISA (Calbiochem, Cambridge, MA, USA) that detects nuclear mitotic apparatus protein (NuMA) released from cells undergoing induced apoptosis (Miller et al, 1993) . Briefly, HT-1197 or HT-1376 cells were treated as described above with MCC or with DNA extracted from MCC. Media from the cell cultures was removed at 0, 3, 6, 24 and/or 48 h, centrifuged at 200 g for 10 min and the supernatant was collected. The supernatant (100 µl) was used for the determination of NuMA protein release by ELISA.
Isolation and treatment of DNA from MCC
Mycobacterial DNA was purified from MCC by conventional phenol extraction and ethanol precipitation (Moore, 1995) . MCC or DNA extracted from MCC was incubated with 1 U of DNAse I (Gibco Life Sciences) for 1 h at 25°C in 20 mM tris-HCl (pH 8.4), 2 mM magnesium chloride and 50 mM potassium chloride. DNAse I was inactivated by the addition of EDTA (final concentration 2.5 mM) and the reaction mixture was heated for 10 min at 65°C. Digestion was confirmed by electrophoresis in 0.7% agarose gels for 3 h at 100 V.
RESULTS
Effect of MCC on cytokine synthesis
A number of cytokines are known to influence the regression or the progression of cancer. IL-12 has been shown to have potent anti-cancer activity by stimulating natural killer (NK) cells or Tcells, and/or in blocking angiogenesis (Voest et al, 1995; Zitvogel and Lotze, 1995; Stern et al, 1996) whereas GM-CSF has the capacity to stimulate the unwanted proliferation of low-grade bladder neoplasms (Hawkyard et al, 1993) . IL-6 has the capacity to stimulate the growth of bladder cancer cells (Okamoto et al, 1997) or to inhibit their proliferation (Alexandroff et al, 1997) . It has also been shown that bladder cancer cells are able to secrete cytokines (De Reijke et al, 1993; Bevers et al, 1997) . We have, therefore, evaluated whether bladder cancer cells or immune effector cells have the ability to synthesize IL-12, IL-6 or GM-C SF in response to MCC. As shown in Figure 1 , IL-12, IL-6 and GM-CSF are not produced by HT-1197 and HT-1376 bladder cancer cells in response to 1.0 µg ml -1 of MCC. However, at this concentration, human THP-1 monocytes and murine macrophages are able to produce significant amounts of IL-12 and IL-6 in response to MCC treatment. Only murine RAW 264.7 cells were able to synthesize GM-CSF. The i.p. administration of MCC to female CD1 mice did not result in the synthesis of GM-CSF, but did, however, induce the synthesis of IL-12 and IL-6 (Figure 2) . Similar results were obtained when MCC was administered i.v. (data not shown).
Inhibition of cancer cell proliferation by MCC
The ability of MCC to directly influence the proliferation of HT-1197 and HT-1376 bladder cancer cells was investigated. MCC is able to inhibit the cellular proliferation of these bladder cancer cells in a dose-dependent manner, whereas the control immunostimulant LPS is without activity (Figure 3) . IL-12 has been shown to reduce the proliferative rate of several cancer cell lines (Izquierdo et al, 1996; Stine et al, 1996) . IL-12 does not inhibit the proliferation of either HT-1197 or HT-1376 bladder cancer cells in the dose range 0.1-100 ng ml -1 (data not shown). To explain this growth inhibition, we have evaluated whether MCC is directly cytotoxic towards these cancer cells. Toxicity is characterized by the loss of plasma membrane integrity and release of the cytoplasmic enzyme LDH (Wyllie et al, 1980) . The release of LDH into the culture supernatant has been used as an indicator of cell death (Phillips et al, 1996) , and human bladder cancer cells have been shown to release LDH when treated with cytotoxic agents (Rahman, 1994) . As shown in Figure 4 , MCC is not cytotoxic towards HT-1376 cells, as determined by the release of LDH into the culture supernatant. Similar results were obtained with HT-1197 cells (data not shown).
Induction of apoptosis by MCC
The lack of a direct cytotoxicity of MCC towards HT-1197 and HT-1376 cancer cells in combination with the antiproliferative activity suggested that MCC is an apoptosis inducer. Apoptosis, or programmed cell death, is associated with nuclear DNA fragmentation, the release of nuclear matrix proteins such as NuMA and the loss of cell-substrate contact (Wyllie et al, 1980; Newell et al, 1990; Miller et al, 1993) . The induction of apoptosis was demonstrated by visualization of nucleosome-sized DNA fragments on agarose gel electrophoresis and by the release of NuMA proteins. MCC at 1.0 µg ml -1 was able to induce apoptosis in both HT-1197 and HT-1376 bladder cancer cells. Nucleosome-sized DNA fragments characteristic of apoptosis were detected in detached HT-1197 and HT-1376 bladder cancer cells after treatment with MCC ( Figure 5 ) MCC also induced the release of NuMA proteins in a dose-related manner ( Figure 6A ). The release of NuMA increased gradually from 3 h to 48 h; a concentration of 100 µg ml -1 MCC being the most effective ( Figure 6B and C) . IL-12, which has been shown to induce apoptosis of several cancer cell lines (Stine et al, 1996) , was unable to induce apoptosis in HT-1197 and HT-1376 bladder cancer cells, as demonstrated by an absence of nucleosome-sized DNA fragments on agarose gel electrophoresis ( Figure 5) .
We have previously shown that MCC contains approximately 5-10% of M. phlei-derived DNA . We have evaluated whether the DNA associated with MCC can induce apoptosis of bladder cancer cells. DNA extracted from MCC is able to induce the release of NuMA from HT-1376 cells, but to a lesser extent than MCC ( El-Demiry et al, 1986; Ioachim-Velogiammi et al, 1994) . IL-12 synthesized by these monocytes and macrophages may make a significant contribution to the overall anti-cancer activity of MCC. IL-12 has been shown to possess potent anti-cancer activity after systemic or local administration in mice bearing a variety of malignancies including melanomas, carcinomas, sarcomas, transitional bladder carcinoma and lymphomas (Brunda et al, 1993; Nastala et al, 1994; Noguchi et al, 1995; Zou et al, 1995 , Chen et al, 1997 . IL-12 plays a role in the development of T-helper type-1 lymphocytes, stimulates γ-interferon (IFN-γ) synthesis, blocks angiogenesis at sites of cancer growth and enhances NK cell and cytotoxic T-cell activity (Voest et al, 1995; Stern et al, 1996; Zitvogel and Lotze, 1996) . Although IL-12 can also exert a direct effect on some cancer cells by inhibiting cellular proliferation through the induction of apoptosis (Stine et al, 1996) , this does not appear to be the case for the two bladder cancer cell lines used in our study. The addition of recombinant human IL-12 to HT-1197 and HT-1376 bladder cancer cells had no direct effect on cellular proliferation, and apoptosis was not induced by IL-12. GM-CSF has been shown to induce the proliferation of bladder cancer cells (Hawkyard et al, 1993) . The results of our study show that MCC does not induce, either in vitro or in vivo, the synthesis of significant quantities of GM-CSF. BCG possesses the ability to up-regulate the synthesis of IL-6 in bladder cancer cells (Esuvaranathan et al, 1995; Sasaki et al, 1997) . The role of IL-6 in bladder cancer outcome is, however, unclear. IL-6 has been shown to function either as a growth factor for bladder cancer lines (Okamoto et al, 1997) , or as an antiproliferative factor (Alexandroff et al, 1997) . We have found that although MCC at 1.0 µg ml -1 does not possess the ability to induce the synthesis of IL-6 by HT-1197 and HT-1376 bladder cancer cells, it does have the ability to induce IL-6 by monocytes and macrophages either in vitro or in vivo.
BCG has been shown to have antiproliferative effects on human bladder cancer cells in vitro in the absence of any immune effector cells (Pryor et al, 1995a (Pryor et al, , 1995b . Similar antiproliferative effects of both heat-killed and viable BCG on a panel of human bladder transitional cell carcinoma cell lines have also been described (Jackson et al, 1994) . However, the mechanism of cellular growth inhibition has not been identified in these studies (Jackson et al, 1994; Pryor et al, 1995a) . Sasaki et al (1997) have shown that the ability of BCG to inhibit the growth of T24 cells was not related to the induction of apoptosis. Other groups have reported an indirect induction of apoptosis in bladder cancer cells by BCG. Shemtov et al (1995) have shown that the human bladder cancer cell line T24 can undergo apoptosis after contact with lymphocyte-activated killer cell (LAK cells), whereas Kudoh et al (1997) have found that BCG-activated lymphocytes are able to induce apotosis of T24 cells via cytokine synthesis. In this study, we have found that the antiproliferative activity of MCC was mediated by the direct induction of apoptosis of human bladder cancer cells and not by a cytotoxic effect. To our knowledge, the present study is the first demonstration of the ability of a mycobacterial cell wall preparation to directly induce apoptosis in cancer cells. We have additionally demonstrated that the apoptosis induced by MCC is related to the presence of mycobacterial DNA in the preparation, and that M. phlei DNA has intrinsic apoptosis-inducing activity. Apoptosis plays an important role in the activity of many anticancer chemotherapeutic agents and in their effectiveness in the treatment of cancer (Dive et al, 1992) . It has been shown, however, that bladder carcinomas are resistant to a number of anti-cancer drugs . Our data show that MCC not only directly induces apoptosis in HT-1197 bladder cancer cells, which are sensitive to doxorubicin, but also directly induces apoptosis in HT-1376 bladder cancer cells, which have been shown to be resistant to several apoptosis-inducing drugs such as cisplatin and mitomycin C (Kawasaki et al, 1996; Mizutani et al, 1997) . Chemotherapy of bladder cancer has been shown to be effective in lowgrade cancers, whereas immunotherapy with BCG appears to be optimally effective in higher grade cancers (Lamm, 1995) . Although highly effective regardless of tumour grade, BCG treatment is preferably reserved for the most aggressive cancer because of its safety profile (Lamm, 1995) . MCC, which appears to possess both a chemotherapeutic-like action against human bladder cancer cells by inducing apoptosis and an indirect BCG-like action by stimulating immune effector cells, has significant promise for the treatment of both low-grade and high-grade bladder cancers. Because mycobacterial cell wall extracts do not contain live bacteria, their safety profile is better (Morales and Chin, 1997) . Further studies investigating the role of apoptosis and IL-12 synthesis induced by MCC using in vivo animal models will be required to clarify the mechanisms implicated in the anti-cancer activity of MCC. MCC and M. phlei DNA associated with MCC are currently being analysed to determine their proapoptotic activity on a number of other bladder cancer cell lines and on freshly derived primary cultures of human bladder carcinoma cells.
